412 ‒ The evolving science of cancer: emerging approaches to prevention and early detection, & more

Early detection has seen advancements beyond traditional discrete imaging, like annual mammograms. There is a focus on continuous monitoring and new imaging technologies. While general blood tests for early cancer detection may lead to false positives in the general population, they show promise for high-risk individuals, such as those with genetic mutations or prior cancers.

Immunotherapy has emerged as a powerful tool, particularly for certain cancers like lung cancer in smokers, by unleashing the immune system to fight cancer cells. CAR T-cell therapy has achieved durable cures in liquid cancers like leukemias and lymphomas. Metabolic therapies, targeting the unique metabolism of cancer cells, are also showing potential as new treatment approaches.

While Bert Vogelstein's work highlighted random mutations, the understanding has evolved. Hereditary mutations are now recognized to include not just single-gene 'shove' mutations (like BRCA1/2) but also 'nudge' mutations involving hundreds of genes. Furthermore, inflammation is understood to be a critical factor that can awaken dormant cancer cells (sleeper cells) carrying mutations, linking bad luck with physiological states.

Obesity is a known risk factor for cancers like endometrial cancer, but it's not a mutagen itself. Instead, the physiological state of obesity, particularly chronic hyperinsulinemia and insulin resistance, is thought to fuel cancer growth and contribute to treatment resistance by sustaining cancerous cells, similar to how inflammation activates dormant cells.

While GLP-1 agonists can reduce hyperinsulinemia, a potential driver of cancer, formal clinical trials for their use as an adjuvant to conventional cancer therapy or for prevention are not yet widespread. However, experts propose such studies for cancers like endometrial or breast cancer, noting the need for thoughtful design.

The thymus is where T-cells mature. AI analysis of CAT scans has shown a correlation between an intact thymus and a lower incidence of autoimmune diseases and cancer. As the thymus naturally involutes with age, its regeneration is being explored as a potential strategy to boost the immune system and prevent age-related diseases, including cancer.

CAR T-cells work by killing specific cell lineages, not just cancer cells. For B-cell leukemias and lymphomas, CAR T-cells target all B-cells, and humans can live without B-cells. However, for solid tumors like brain or pancreatic cancer, the targeted antigens are often too similar to normal cells in vital organs, making it impossible to remove all cells without causing severe damage or death. The strategy needs to evolve to target unique antigens or organs that can be removed without fatal consequences.

Pancreatic cancer is devastating due to its anatomical location, often involving complex surrounding structures, making surgical removal challenging and early detection rare. While incidental findings in the 'tail' of the pancreas can lead to better outcomes, 'head' cancers are very aggressive. New treatments like Daxsonrasib target KRAS mutations common in pancreatic cancer, and ongoing trials are exploring their use as adjuvant therapy after surgery to reduce tumor burden.

The exact causes are unknown, but speculation points to rapid changes in the colorectal milieu over recent decades. Factors include increased ingestion of 'forever chemicals' that can be pro-inflammatory, disruptions to the gut microbiome from antibiotics and diet, and significantly lower fiber intake compared to historical diets.

AI is significantly impacting drug discovery by accelerating synthetic molecular design. Instead of relying on traditional search-and-fit methods or chemists with vast knowledge, AI can be taught the rules of chemistry and physics to generate new molecules from scratch, effectively scaling the capabilities of top chemists to design keys for biological locks.

The ultimate goal for cancer prevention will be chemo-prevention, where drugs could prevent cancer similar to how Lipitor prevents heart attacks. While lifestyle changes are important, the hope is for targeted molecules that can intervene in the underlying physiological states, such as inflammation or insulin resistance, that drive cancer development.

The 'orthogonal' view posits that longevity isn't solely about preventing specific pathological diseases like cancer or heart disease. Instead, it focuses on achieving a physiological state that reduces all diseases, including those of regeneration (e.g., osteoarthritis, immune failure, bone marrow failure). This approach seeks to address the fundamental processes of aging rather than just individual diseases.

The NIH's current mandate primarily focuses on studying and treating illness rather than promoting wellness or systematically addressing the fundamental processes of aging and regenerative failure. While the National Institute of Aging exists, a comprehensive 'Manhattan Project' for longevity would require a broader mandate and significant, long-term funding, possibly from philanthropists, to support the necessary basic science before drug discovery.